Open AccessA highly secreted sulphamidase engineered to cross the blood‐brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA
Author(s) -
Sorrentino Nicolina Cristina,
D'Orsi Luca,
Sambri Irene,
Nusco Edoardo,
Monaco Ciro,
Spampanato Carmine,
Polishchuk Elena,
Saccone Paola,
De Leonibus Elvira,
Ballabio Andrea,
Fraldi Alessandro
Publication year - 2013
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.1002/emmm.201202083
Subject(s) - transcytosis , enzyme replacement therapy , blood–brain barrier , genetic enhancement , pharmacology , medicine , lysosomal storage disease , recombinant dna , biology , pathology , central nervous system , gene , receptor , disease , biochemistry , endocytosis
Mucopolysaccharidoses type IIIA (MPS‐IIIA) is a neurodegenerative lysosomal storage disorder (LSD) caused by inherited defects of the sulphamidase gene. Here, we used a systemic gene transfer approach to demonstrate the therapeutic efficacy of a chimeric sulphamidase, which was engineered by adding the signal peptide (sp) from the highly secreted iduronate‐2‐sulphatase (IDS) and the blood‐brain barrier (BBB)‐binding domain (BD) from the Apolipoprotein B (ApoB‐BD). A single intravascular administration of AAV2/8 carrying the modified sulphamidase was performed in adult MPS‐IIIA mice in order to target the liver and convert it to a factory organ for sustained systemic release of the modified sulphamidase. We showed that while the IDS sp replacement results in increased enzyme secretion, the addition of the ApoB‐BD allows efficient BBB transcytosis and restoration of sulphamidase activity in the brain of treated mice. This, in turn, resulted in an overall improvement of brain pathology and recovery of a normal behavioural phenotype. Our results provide a novel feasible strategy to develop minimally invasive therapies for the treatment of brain pathology in MPS‐IIIA and other neurodegenerative LSDs. →See accompanying article emmm.201302668